PATENT CLAIM ANALYSIS

Application Number: 15746964
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-11
Patent Classification: ["514", "168000"]

Abstract:
The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

Claim (Index 12):
The pharmaceutical composition of  claim 11 , wherein the second therapeutic agent is a mitotic inhibitor (such as taxanes (preferably paclitaxel, docetaxel),  vinca  alkaloids (preferably, vinblastine, vincristine, vindesine and vinorelbine) and vepesid; an anthracycline antibiotic (such as doxorubicin, daunorubicin, daunorubicin, epirubicin, idarubicin, valrubicin and mitoxantrone); a nucleoside analog (such as gemcitabine); an EGFR inhibitor (such as gefitinib and erlotinib); a folate antimetabolite (such as trimethoprim, pyrimethamine and pemetrexed); cisplatin, carboplatin or an HDAC inhibitor.

Metadata:
- Claim Count in Document: 30.0
- Percentile: 86.0
- Lexical Diversity: 1.36111
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12555018', '12309459', '14790978', '13906626', '14592801']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8047869307648561
- 35 USC 102 Novelty (BERT): 0.5115845094434838
- Combined Prediction Score: 0.7754666886327188
- Mean Citation Score: 266.204172
- Max Citation Score: 272.8594
- Similarity Product: 185.6403334448576

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test